On June 23, 2021 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported a comprehensive update on its discovery and clinical-stage pipeline at its 2021 virtual R&D Day (Press release, Jounce Therapeutics, JUN 23, 2021, View Source [SID1234584273]). Presentations will highlight Jounce’s productive discovery engine and platform, updates on its discovery pipeline, and progress on the clinical development of JTX-8064. In addition to presentations from Jounce management and scientific team members, key opinion leader and one of Jounce’s scientific founders, Robert Schreiber, Ph.D., Distinguished Professor of Pathology and Immunology at The Washington University School of Medicine, will discuss the scientific rationale for targeting myeloid cells and the therapeutic potential of re-programming macrophages through inhibition of LILRB2.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Jounce is at an exciting time in its life cycle and I am incredibly pleased to have the opportunity to share the latest developments on our discovery and clinical stage pipelines, while also sharing a look into our productive and validated Translational Science Platform. More specifically, we will discuss the monotherapy dose escalation status of our INNATE trial of JTX-8064. Thanks to a high level of investigator engagement and dedicated efforts from our team, the timing of expansion cohort initiations is now expected in the third quarter of this year," said Richard Murray, Ph.D., Chief Executive Officer and President of Jounce Therapeutics. "Our pipeline has been built to bring forward new biomarker-enabled immunotherapies to address the evolving unmet needs of cancer patients, whose tumors may be sensitive or resistant to today’s approved immunotherapies."

"One of the key attributes of Jounce’s approach to immuno-oncology is its expertise in developing molecules that target a diverse set of immune cell types within the tumor microenvironment. Through the work of our platform, we have a greater understanding of how immune suppressive macrophages and LILRB2 itself can serve as negative prognostic indicators in several tumor types," said Dmitri Wiederschain, Ph.D., Chief Scientific Officer of Jounce Therapeutics. "We believe that the LILRB family represents attractive immuno-oncology targets with the potential to improve upon and restore responsiveness to PD-(L)1 inhibitors. As such, we are pleased to announce that we are rapidly advancing two additional LILRB family programs through discovery, targeting LILRB1 and LILRB4."

R&D Day Presentation Highlights Include:

Utilization of Jounce’s Translational Science Platform to investigate the tumor microenvironment and identify cell type-specific targets with unique biology
Overview of differentiated biomarker approach from discovery through development
Introduction of new discovery programs focused on additional LILRB family members, including LILRB1 and LILRB4
Update on monotherapy dose escalation and receptor occupancy from the INNATE clinical trial of JTX-8064
Announcement of timing of INNATE clinical trial monotherapy and pimivalimab combination expansion cohort initiation, expected in the third quarter of 2021
Update on continued progress on Jounce’s first biomarker patient selection study, SELECT
Anticipated Milestones:

JTX-8064 (INNATE):
Establish recommended Phase 2 dose
Initiate tumor-specific monotherapy and pimivalimab combination expansion cohorts beginning in the third quarter of 2021
Vopratelimab (SELECT):
Patient enrollment to support clinical data in 2022
Continue to advance multiple new targets through discovery pipeline with goal of an investigational new drug (IND) every 12-18 months
Webcast Details:
A webcast of the R&D Day will be available by visiting "Events and Presentations" in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcast will be available for 30 days following the presentation.